Обзор рекомендаций американского общества по инфекционным болезням по лечению аспергиллёза | КМАХ

Обзор рекомендаций американского общества по инфекционным болезням по лечению аспергиллёза

Клиническая Микробиология и Антимикробная Химиотерапия. 2008; 10(2):96-142

​ Масчан А.А., Клясова Г.А., Веселов А.В.
инвазивный аспергиллёз Aspergillus химиотерапия
Раздел
Методические рекомендации
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 2008; 10(2):96-142

Аннотация

Поражения, вызванные грибами рода Aspergillus, известны очень давно, однако инвазивный аспергиллёз возник в качестве важнейшей проблемы медицины сравнительно недавно, а именно — в последние 30 лет после доказательства принципиальной излечимости гемопоэтических опухолей с помощью химиопрепаратов. Публикуемые рекомендации являются полным и на данный момент исчерпывающим документом, дающим в руки клинициста важный инструмент борьбы с такой грозной группой заболеваний, которой объединяемых в понятие аспергиллёз.

  • 1. Eggimann P., Pittet D. Infection control in the ICU. Chest 2001; 120: 2059-93.
  • 2. Weber D.J., Raasch R., Rutala W.A. Nosocomial infections in the ICU: the growing importance of antibioticresistant pathogens. Chest 1999; 115:34-41.
  • 3. Vincent J.L., Bihari D.J., Suter P.M., et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274:639-44.
  • 4. Heyland D.K., Cook D.J., Griffith L., Keenan S.P., BrunBuisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Resp Crit Care Med 1999; 159:1249-56.
  • 5. Plowman R., Graves N., Griffin M.A.S., Roberts J.A., Swan A.V., Cookson B., et al. The rate and cost of hospital-acquired infections occurring in patients admitted to selected specialties of a district general hospital in England and the national burden imposed. J Hosp Infect 2001; 47:198-209.
  • 6. Stephen J., Mutnick A., Jones R.N. Assessment of pathogens and resistance (R) patterns among intensive care unit (ICU) patients in North America (NA): initial report from the SENTRY Antimicrobial Surveillance Program (2001). Abstract C2-29
  • 7. In: Programs and Abstracts of the 42nd Interscience Congress of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Diego, CA. 2002. 7. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 14th informational supplement. NCCLS document M100-S14. 2004. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: 13th informational supplement. NCCLS document M100-S13 2003. National Committee for Clinical Laboratory Standards, Wayne, PA.
  • 9. Comite de l’antibiogramme de la Societe Francaise de Microbiologie. Report 2003.
  • 10. Страчунский Л.С., Решедько Г.К., Рябкова Е.Л., Стецюк О.У., Кречикова О.И., Суина З.М. и др. Рекомендации по оптимизации антимикробной терапии нозокомиальных инфекций, вызванных грамотрицательными бактериями в отделениях реанимации и интенсивной терапии. Клин Микроб Антимикроб Химиотер 2002; 4:379-90.
  • 11. Gaynes R., Edwards J.R., and the National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005; 41:848-54.
  • 12. Gales A.C., Jones R.N., Sader H.S. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001- 2004). Clin Microbiol Infect 2006; 12:315-21.
  • 13. Unal S., Garcia-Rodriguez J.A. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinteobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn Microbiol Infect Dis 2005; 53:256-71.
  • 14. Jones R.N., Sader H.S., Beach M.L. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gramnegative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int J Antimicrob Agents 2003; 22:551-6.
  • 15. Karlowsky J.A., Draghi D.C., Jones M.E., Thornsberry C., Friedland I.R., Sahm D.F. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003: 47:1681-8.
  • 16. Reinert R.R., Low D.E., Rossi F., Zhang X., Wattal C., Dowzicky M.J. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60:1018-29.
  • 17. Obritsch M.D., Fish D.N., MacLaren R., Jung R. national surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48:4606-10.
  • 18. Lockhart S.R., Abramson M.A., Beekmann S.E., Gallagher G., Riedel S., Diekema D.J., Quinn J.P., Doern G.V. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007; 45:3352-9.
  • 19. Bergogne-Berezin E., Towner K.J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996; 9:148-65.
  • 20. Navon-Venezia S., Ben-Ami R., Carmeli Y. Update on Pseudomonas aeruginosa and Acinetobacter baumannii infections in the healthcare setting. Curr Opin Infect Dis 2005; 18:306-13.
  • 21. Clark R.B. Imipenem resistance among Acinetobacter baumannii: association with reduced expression of a 33-36 kDa outer membrane protein. J Antimicrob Chemother 1996; 38:245-51.
  • 22. Gupta V., Datta P., Agnihotri N., Chander J. Comparative in vitro activities of seven new beta-lactams, alone and in combination with beta-lactamase inhibitors, against clinical isolates resistant to third generation cephalosporins. Braz J Infect Dis 2006; 10:22-5.
  • 23. Ishii Y., Alba J., Kimura S., Yamaguchi K. Evaluation of antimicrobial activity of beta-lactam antibiotics by Etest against clinical isolates from 100 medical centers in Japan (2004). Diagn Microbiol Infect Dis 2006; 55:143-8.
  • 24. Yamaguchi K., Mathai D., Biedenbach D.J., Lewis M.T., Gales A.C., Jones R.N. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1999; 34:123-34.
  • 25. Jones R.N., Salazar J.C., Pfaller M.A., Doern G.V. Multicenter evaluation of antimicrobial resistance to six broadspectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis 1997; 29:265-72.
  • 26. Turner P.J., Greenhalgh J.M.; MYSTIC Study Group (Europe). The activity of meropenem and comparators against Acinetobacter strains isolated from European hospitals, 1997-2000. Clin Microbiol Infect 2003; 9:563-7.
  • 27. Johnson J., Badal R., Hoban D., Johnson B., Bouchillon S., Stevens T., Hsiung A., Dowzicky M. Tigecycline in vitro activity against in-patient and out-patient pathogens collected from centers in Europe – T.E.S.T. Programm 2006. Abstract 493. In: Programs and Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, 2006.
  • 28. Neuhauser M.M., Weinstein R.A., Rydman R., Danziger L.H., Karam G., Quinn J.P. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 2003; 289:885-8.
  • 29. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
  • 30. Nijssen S., Florjin A., Bonten M.J.M., Schmitz F.J., Verhoef J., Fluit A.C. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates. Int J Antimicrob Agents 2004; 24:585-91.
  • 31. Winokur P.L., Canton R., Casellas J.M., Legakis N. Variations in prevalence of strains expressing an extendedspectrum β-lactamase phenotype and characterization of isolates Europe, the Americas and the Western Pacific region. Clin Infect Dis 2001; 32 (Suppl 2):S94-103.
  • 32. Garcia-Rodriguez J.-A., Jones R.N. and the MYSTIC Programme Study Group. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme. J Chemother 2002; 14:25-32.
  • 33. Hoban D., Johnson B., Bouchillon S., Stevens T., Badal R., Johnson J., Hsiung A., Dowzicky M. In vitro activity of tigecylcine and comparators against community and hospital acquired infections in the United States – T.E.S.T. Programm 2006. Abstract 1318. In: Programs and Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, 2006.
  • 34. Naas T., Nordmann P., Vedel G., Poyart C. Plasmidmediated carbapenem-hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423-4.
  • 35. Yigit H., Queenan A.-M., Anderson G.I., DomenechSanchez A., Biddle J.W., Steward C.D., Alberti S., Bush K., Tenover F.C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151-61.
  • 36. Livermore D.M., Carter M.W., Bagel S., Wiedemann B., Baquero F., Loza E. et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001; 45:1860-7.
  • 37. Fuchs P.C., Barry A.L., Brown S.D. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001; 45:1915–8.
  • 38. Jacoby G.A., Mills D.M., Chow N. Role of β-lactamase and porins in resistance to ertapenem and other β-lactams in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48:3203-6.
  • 39. Jones R.N., Biedenbach D.J., Gales A.C. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Intern J Antimicrob Agents 2003; 21:1-7.
  • 40. Wenzel R.P., Sahm D.F., Thornsberry C., Draghi D.C., Jones M.E., Karlowsky J.A. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob Agents Chemother 2003; 47:3089–98.
  • 41. Fritsche T.R., Stilwell M.G., Jones R.N. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microb Infect 2005; 11:974-84.
  • 42. Rhomberg P.R., Jones R.N. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007; 57:207- 15.
  • 43. Hoban D., Bouchillon S., Johnson B., Stevens T., Johnson J., Hsiung A., Badal R., Dowzicky M. Tigecylcine in vitro activity in current European pathogens - T.E.S.T. Programm 2006. Abstract P490. In: Programs and Abstracts of the 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, 2006.
  • 44. Cermak P., Kolar M., Latal T. Frequency of gram-negative bacterial pathogens in bloodstream infections and their resistance to antibiotics in the Czech Republic. Intern J Antimicrob Agents 2004; 23:401-4.
  • 45. Streit J.M., Jones R.N., Sader H.S., Fritshce T.R. Assessment of pathogen occurrence and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Programm (North America, 2001). Int J Antimicrob Agents 2004; 24:111-8.
  • 46. Страчунский Л.С., Решедько Г.К., Эйдельштейн М.В., Стецюк О.У., Рябкова Е.Л., Андреева А.С., исследовательская группа РОСНЕТ. Сравнительная активность цефепима и других антибиотиков в отношении нозокомиальных грамотрицательных возбудителей в России. Клиническая Микробиология и Антимикробная Химиотерапия 2003; 5:259-74.
  • 47. Страчунский Л.С., Решедько Г.К., Стецюк О.У., Андреева А.С., Щебников А.Г., исследовательская группа РОСНЕТ. Сравнительная активность антисинегнойных антибиотиков в отношении нозокомиальных штаммов Pseudomonas aeruginosa, выделенных в отделениях реанимации и интенсивной терапии России. Клин Микроб Антимикроб Химиотер 2003; 5:35-46.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились